Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL -Rearrangements: A Novel Therapeutic Strategy for Pediatric AML

Cancers
Annalisa LonettiRiccardo Masetti

Abstract

Pediatric acute myeloid leukemia (AML) is an aggressive malignancy with poor prognosis for which there are few effective targeted approaches, despite the numerous genetic alterations, including MLL gene rearrangements (MLL-r). The histone methyltransferase DOT1L is involved in supporting the proliferation of MLL-r cells, for which a target inhibitor, Pinometostat, has been evaluated in a clinical trial recruiting pediatric MLL-r leukemic patients. However, modest clinical effects have been observed. Recent studies have reported that additional leukemia subtypes lacking MLL-r are sensitive to DOT1L inhibition. Here, we report that targeting DOT1L with Pinometostat sensitizes pediatric AML cells to further treatment with the multi-kinase inhibitor Sorafenib, irrespectively of MLL-r. DOT1L pharmacologic inhibition induces AML cell differentiation and modulates the expression of genes with relevant roles in cancer development. Such modifications in the transcriptional program increase the apoptosis and growth suppression of both AML cell lines and primary pediatric AML cells with diverse genotypes. Through ChIP-seq analysis, we identified the genes regulated by DOT1L irrespective of MLL-r, including the Sorafenib target BRAF, provi...Continue Reading

References

Sep 3, 2003·Nature Reviews. Cancer·Derek L Stirewalt, Jerald P Radich
Apr 27, 2005·Cell·Yuki OkadaYi Zhang
Aug 22, 2006·Nature Cell Biology·Yuki OkadaYi Zhang
Feb 21, 2008·Molecular and Cellular Biology·David J StegerChristopher R Vakoc
Nov 4, 2008·Cancer Cell·Andrei V KrivtsovScott A Armstrong
Oct 19, 2010·Haematologica·Gautam BorthakurJorge E Cortes
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ching-Hon PuiRobert J Arceci
Jul 5, 2011·Genes & Development·Anh Tram Nguyen, Yi Zhang
Jul 12, 2011·Cancer Cell·Kathrin M BerntScott A Armstrong
Sep 11, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brigitte C WidemannSusan M Blaney
Jun 27, 2013·Blood·Scott R DaigleRoy M Pollock
May 27, 2014·PloS One·Wei LiuMichele Redell
Jan 18, 2015·Haematologica·Michael W M KühnScott A Armstrong
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Michel ZwaanGertjan J L Kaspers
Jun 14, 2016·Nature Structural & Molecular Biology·Omer GilanMark A Dawson
Aug 19, 2016·Cancer Discovery·Michael W M KühnScott A Armstrong
Jan 19, 2018·OncoTargets and Therapy·Germana CastelliUgo Testa
Dec 5, 2018·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Xin HeZhigang Chen
Mar 2, 2019·International Journal of Molecular Sciences·Anna SkuchaFlorian Grebien

❮ Previous
Next ❯

Methods Mentioned

BETA
ChIP-seq
flow cytometry
PMA

Clinical Trials Mentioned

NCT02141828
NCT01684150

Software Mentioned

GraphPad Prism
GSEA

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.